Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
660
Trial Sponsor
Trial Collaborator
0
Clinical Trial Start Date
2010
0Primary Completion Date
June 14, 2022
0Study Completion Date
June 14, 2022
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
margetuximab0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available0
Last Updated
October 19, 2022
0Allocation Type
Non-Randomized0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
